Log in

Relevant bibliographies by topics / Cost-effectiveness model / Journal articles

To see the other types of publications on this topic, follow the link: Cost-effectiveness model.

Journal articles on the topic 'Cost-effectiveness model'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cost-effectiveness model.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Grosse, Robert N., and Robert L. Tilden. "Vitamin a cost-effectiveness model." International Journal of Health Planning and Management 3, no. 4 (October 1988): 225–44. http://dx.doi.org/10.1002/hpm.4740030403.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Tonjes, David J., and Sreekanth Mallikarjun. "Cost effectiveness of recycling: A systems model." Waste Management 33, no. 11 (November 2013): 2548–56. http://dx.doi.org/10.1016/j.wasman.2013.06.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Russell, Louise B. "Comparing Model Structures in Cost-Effectiveness Analysis." Medical Decision Making 25, no. 5 (September 2005): 485–86. http://dx.doi.org/10.1177/0272989x05281155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Rabuş, Şule Apikoğlu, Fikret Vehbi lzzettin, Mesut Sancar, Murat Bülent Rabuş, Cevat Kırma, and Cevat Yakut. "Cost-Effectiveness of Thrombolytics: A Simplified Model." Pharmacy World & Science 27, no. 3 (June 2005): 243–48. http://dx.doi.org/10.1007/s11096-004-4097-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lieberman, David A. "Cost-effectiveness model for colon cancer screening." Gastroenterology 109, no. 6 (December 1995): 1781–90. http://dx.doi.org/10.1016/0016-5085(95)90744-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Crowe, B. L. "Cost-effectiveness analysis of telemedicine." Journal of Telemedicine and Telecare 4, no. 1_suppl (March 1998): 14–17. http://dx.doi.org/10.1258/1357633981931867.

Full text

Abstract:

There are a number of different costs associated with the development and operation of telemedicine services. A model is proposed in order to assist in strengthening the evidence base for telemedicine. It includes the following components: project establishment costs; equipment costs; maintenance costs; communication costs; staffing costs. All need to be considered in arriving at an annual cost figure for operating a telemedicine service. The inclusion of all these costs, prepared in the standard manner outlined in the model, will ensure that a realistic cost figure is available when evaluating the cost-effectiveness of a telemedicine service.

APA, Harvard, Vancouver, ISO, and other styles

7

Fryback, Dennis G., James O. Chinnis, and Jacob W. Ulvila. "BAYESIAN COST-EFFECTIVENESS ANALYSIS." International Journal of Technology Assessment in Health Care 17, no. 1 (January 2001): 83–97. http://dx.doi.org/10.1017/s0266462301104083.

Full text

Abstract:

A desirable element of cost-effectiveness analysis (CEA) modeling is a systematic way to relate uncertainty about input parameters to uncertainty in the computational results of the CEA model. Use of Bayesian statistical estimation and Monte Carlo simulation provides a natural way to compute a posterior probability distribution for each CEA result. We demonstrate this approach by reanalyzing a previously published CEA evaluating the incremental cost-effectiveness of tissue plasminogen activator compared to streptokinase for thrombolysis in acute myocardial infarction patients using data from the GUSTO trial and other auxiliary data sources. We illustrate Bayesian estimation for proportions, mean costs, and mean quality-of-life weights. The computations are performed using the Bayesian analysis software WinBUGS, distributed by the MRC Biostatistics Unit, Cambridge, England.

APA, Harvard, Vancouver, ISO, and other styles

8

Ramsberg, Joakim, Christian Asseburg, and Martin Henriksson. "Effectiveness and Cost-Effectiveness of Antidepressants in Primary Care: A Multiple Treatment Comparison Meta-Analysis and Cost-Effectiveness Model." PLoS ONE 7, no. 8 (August 2, 2012): e42003. http://dx.doi.org/10.1371/journal.pone.0042003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Woods, Scott W., and John A. Rizzo. "Cost-effectiveness of antidepressant treatment reassessed." British Journal of Psychiatry 170, no. 3 (March 1997): 257–63. http://dx.doi.org/10.1192/bjp.170.3.257.

Full text

Abstract:

BackgroundA recent simulation concluded that the serotonin-specific reuptake inhibitor (SSRI) paroxetine was more cost-effective than the tricyclic antidepressant (TCA) imipramine, despite substantially higher medication acquisition costs.MethodWe replicated the previous model and revised key assumptions which drove the results. The revised model was subjected to sensitivity analysis.ResultsMost scenarios in the revised model showed that the TCA is equally or more cost-effective than the SSRI. Model revision producing these results were changes in assumptions about switched treatment success rates, treatment length and initial treatment success. The revised model appears sensitive to drug acquisition and delivery costs and costs of treatment failure.ConclusionsBased on the model, a policy of using TCAs as first-choice antidepressant treatment, with SSRIs reserved for those patients not doing well initially, appears more cost-effective than the reverse sequence. Given limitations in current knowledge about key parameters to include in a simulation model, large prospective random-assignment cost-effectiveness studies are needed.

APA, Harvard, Vancouver, ISO, and other styles

10

Nields, Morgan W., and Richard R. Galaty. "Digital mammography: A model for assessing cost-effectiveness." Academic Radiology 5 (September 1998): S310—S313. http://dx.doi.org/10.1016/s1076-6332(98)80340-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Newhall, Karina, Benjamin Albright, Anna Tosteson, Elissa Ozanne, Thadeus Trus, and Philip P. Goodney. "Cost-effectiveness of prophylactic appendectomy: a Markov model." Surgical Endoscopy 31, no. 9 (January 11, 2017): 3596–604. http://dx.doi.org/10.1007/s00464-016-5391-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

van Haalen, H. G. M., J. L. Severens, A. Tran-Duy, and A. Boonen. "How to Select the Right Cost-Effectiveness Model?" PharmacoEconomics 32, no. 5 (February 7, 2014): 429–42. http://dx.doi.org/10.1007/s40273-014-0139-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Вартанов, Сергей, Ирина Богатова, Ирина Денисова, Валериан Кучеряну, Наталья Турдыева, Татьяна Чубарова, Марина Шаклеина, and Виктор Полтерович. "Экономическая эффективность доклинической диагностики болезни Паркинсона: марковская модель." ИЗВЕСТИЯ ДАЛЬНЕВОСТОЧНОГО ФЕДЕРАЛЬНОГО УНИВЕРСИТЕТА. ЭКОНОМИКА И УПРАВЛЕНИЕ, no. 4 (2020): 129–48. http://dx.doi.org/10.24866/2311-2271/2020-4/129-148.

Full text

Abstract:

Работа посвящена фармакоэкономическому анализу результатов внедрения ранней (доклинической) диагностики болезни Паркинсона в России. На основе совокупности социально-экономических детерминант и панели биомаркеров крови может оказаться возможным выделение среди всей популяции «группы риска» людей, с наибольшей вероятностью склонных к возникновению паркинсонизма либо уже больных им на доклинической стадии. Вкупе с традиционно используемым в фармакоэкономике хронических и продолжительных заболеваний подходом, основанным на представлении динамики развития болезни с помощью марковских цепей – дискретных случайных процессов без памяти – это делает возможным анализ экономических эффектов от раннего выявления заболевших и проведения профилактической доклинической терапии. В работе исследована марковская модель болезни Паркинсона, состоящая из восьми состояний – пять состояний, соответствующих стадиям HY1-HY5, два доклинических состояния («группа риска», «продромальное состояние»). Используя в качестве исходных данных для модели вероятности перехода между состояниями и оценки качества жизни, скорректированные с учетом здоровья (HRQoL), опубликованные в ряде работ аффилированных с корпорацией AbbVie исследователей, и рассчитав затраты на терапию на основе открытых данных о стоимости лекарств и процедур на российском рынке (eapteka, apteka.ru, piluli.ru, сайт Минздрава РФ), в работе показано, что за счет внедрения доклинической диагностики и проведения профилактического лечения на доклинических стадиях выявленным пациентам возможно значительно увеличить среднее время дожития (в годах, скорректированных по качеству жизни) по сравнению со стандартной терапией, а средние затраты на одного пациента до конца жизни – значительно снизить. This article contains a pharmacoeconomic analysis of early (preclinical) diagnosis of Parkinson's disease in Russia. Previous works show that using a combination of socio-economic determinants and a panel of blood biomarkers one may distinguish a Parkinsonism-related “risk group” among the entire population. This group consists of people who are most vulnerable to parkinsonism or are already ill, but at the preclinical stage. Together with the approach traditionally used in the pharmacoeconomics of chronic and long-term diseases, based on the representation of the dynamics of the development of the disease using Markov chains - discrete random processes without memory - this makes it possible to analyze the economic effects of early detection of cases and conducting preventive preclinical therapy. The work investigates the Markov model of Parkinson's disease, consisting of nine states - five states corresponding to the stages HY1-HY5, two preclinical states ("risk group", "prodromal state"). We use as the initial data for the model the probability of transition between states and health-adjusted quality of life (HRQoL) estimates, published in a number of works of researchers affiliated with AbbVie Corporation, and calculate the cost of therapy based on open data on the cost of drugs and procedures in Russian market. Moreover, we show that due to the introduction of preclinical diagnostics and preventive treatment at preclinical stages, identified patients can significantly increase the average survival time (in quality-adjusted life-years) compared to standard therapy, and the average cost per patient until the end of life can be significantly reduced.

APA, Harvard, Vancouver, ISO, and other styles

14

Lim, Jaims, Alan R. Tang, Campbell Liles, Alexander A. Hysong, Andrew T. Hale, Christopher M. Bonfield, Robert P. Naftel, John C. Wellons, and Chevis N. Shannon. "The cost of hydrocephalus: a cost-effectiveness model for evaluating surgical techniques." Journal of Neurosurgery: Pediatrics 23, no. 1 (January 2019): 109–18. http://dx.doi.org/10.3171/2018.6.peds17654.

Full text

Abstract:

OBJECTIVEMany studies have aimed to determine the most clinically effective surgical intervention for hydrocephalus. However, the costs associated with each treatment option are poorly understood. In this study, the authors conducted a cost-effectiveness analysis, calculating the incremental cost-effectiveness ratio (ICER) of ventriculoperitoneal shunting (VPS), endoscopic third ventriculostomy (ETV), and ETV with choroid plexus cauterization (ETV/CPC) in an effort to better understand the clinical effectiveness and costs associated with treating hydrocephalus.METHODSThe study cohort includes patients under the age of 18 who were initially treated for hydrocephalus between January 2012 and January 2015 at the authors’ institution. Overall treatment costs were calculated using patient-level hospitalization costs and professional fees reimbursable to the hospital and directly related to the initial and follow-up (postoperative day 1 to 12 months) treatment of hydrocephalus. TreeAge Pro was used to conduct the cost-effectiveness analyses.RESULTSA total of 147 patients were identified. Based on the initial intervention for hydrocephalus, their cases were classified as follows: 113 VPS, 14 ETV, and 20 ETV/CPC. During the initial intervention, VPS patients required a longer length of stay at 5.6 days, compared to ETV/CPC (3.35 days) and ETV (2.36 days) patients. Failure rates for all treatment options ranged from 29% to 45%, leading to recurrent hydrocephalus and additional surgical intervention between postoperative day 1 and 12 months. Cost-effectiveness analyses found ETV to be less costly and more clinically effective, with an ICER of $94,797 compared to VPS ($130,839) and ETV/CPC ($126,394). However, when stratified by etiology, VPS was found to be more clinically effective and cost-effective in both the myelomeningocele and posthemorrhagic hydrocephalus patient groups with an incremental cost per clinical unit of effectiveness (success or failure of intervention) of $76,620 compared to ETV and ETV/CPC. However, when assessing cases categorized as “other etiologies,” ETV was found to be more cost-effective per clinical unit, with an ICER of $60,061 compared to ETV/CPC ($93,350) and VPS ($142,135).CONCLUSIONSThis study is one of the first attempts at quantifying the patient-level hospitalization costs associated with surgical management of hydrocephalus in pediatric patients treated in the United States. The results indicate that the conversation regarding CSF diversion techniques must be patient-specific and consider etiology as well as any previous surgical intervention. Again, these findings are short-run observations, and a long-term follow-up study should be conducted to assess the cost of treating hydrocephalus over the lifetime of a patient.

APA, Harvard, Vancouver, ISO, and other styles

15

Weinstein, Sue M. "Cost-Effectiveness Analysis in Mental Health." Canadian Journal of Community Mental Health 5, no. 1 (April 1, 1986): 77–88. http://dx.doi.org/10.7870/cjcmh-1986-0007.

Full text

Abstract:

As costs rise and demands for services increase, governments are beginning to insist that mental health program administrators demonstrate that they are “worthwhile” in terms of results produced (outcomes) for money invested (costs). Cost-effectiveness analysis, one economic evaluation model, is presented as a potentially useful tool that can be employed in mental health settings. An overview of the definition, underlying assumptions, and procedures of cost-effectiveness analysis is provided. Issues relating to the manner in which cost and effectiveness information is presented to decision makers along with associated decision rules are also reviewed. It is concluded that it is difficult to “buy” the cost-effectiveness model as it now exists. Modifications in its assumptions, data gathering and data combination techniques are warranted so that the model can be applicable to mental health settings and policies. The general theme underlying suggested modifications is that values and constraints associated with all aspects of a cost-effectiveness problem must be made explicit and should guide analytic procedures.

APA, Harvard, Vancouver, ISO, and other styles

16

Nuijten, MJ, M. Lebmeier, P. Daalderop, and W. Wittenberg. "PIH1 COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE NETHERLANDS." Value in Health 8, no. 6 (November 2005): A52. http://dx.doi.org/10.1016/s1098-3015(10)67298-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Nuijten, MJ, M. Lebmeier, and W. Wittenberg. "PIN23 COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE UK." Value in Health 8, no. 6 (November 2005): A62. http://dx.doi.org/10.1016/s1098-3015(10)67331-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Bahn, O., and A. Haurie. "A Cost-Effectiveness Differential Game Model for Climate Agreements." Dynamic Games and Applications 6, no. 1 (February 5, 2015): 1–19. http://dx.doi.org/10.1007/s13235-015-0141-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

ELLIOT, DIANE L., LINN GOLDBERG, and MARCELLA LOPRINZI. "Management of suspected iron deficiency a cost-effectiveness model." Medicine & Science in Sports & Exercise 23, no. 12 (December 1991): 1332???1337. http://dx.doi.org/10.1249/00005768-199112000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Laffel, Glenn L., Harvey V. Fineberg, and Eugene Braunwald. "A cost-effectiveness model for coronary thrombolysis/reperfusion therapy." Journal of the American College of Cardiology 10, no. 5 (November 1987): 79B—90B. http://dx.doi.org/10.1016/s0735-1097(87)80432-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Lutz, James B. "AN ECONOMIC MODEL COMPARING COST-EFFECTIVENESS OF TWO DRESSINGS." Journal of Wound, Ostomy and Continence Nursing 30, no. 3 (May 2003): S20—S21. http://dx.doi.org/10.1097/00152192-200305000-00077.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Wordsworth, S., J. Leal, E. Blair, R. Legood, K. Thomson, A. Seller, J. Taylor, and H. Watkins. "DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model." European Heart Journal 31, no. 8 (March 18, 2010): 926–35. http://dx.doi.org/10.1093/eurheartj/ehq067.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Conigliani, Caterina, and Andrea Tancredi. "A Bayesian model averaging approach for cost-effectiveness analyses." Health Economics 18, no. 7 (July 2009): 807–21. http://dx.doi.org/10.1002/hec.1404.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Earnshaw, Stephanie R., Andrew P. Brogan, and Cheryl L. McDade. "Model-Based Cost-Effectiveness Analyses for Prostate Cancer Chemoprevention." PharmacoEconomics 31, no. 4 (March 22, 2013): 289–304. http://dx.doi.org/10.1007/s40273-013-0037-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Barry, Jean-Cyriaque, Andreas Hartmann, Uwe M. Pongs, and Martina Jöckel. "A model for cost-effectiveness ratios in amblyopia screening." Der Ophthalmologe 95, no. 1 (February 3, 1998): 19–27. http://dx.doi.org/10.1007/s003470050230.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

PRASANTHI RASHMI, N., CH RADHAKUMARI, and N. SAI PRANAV. "BUSINESS MODEL FRAMEWORK AND COST EFFECTIVENESS OF IoT SOLUTIONS." i-manager's Journal on Computer Science 8, no. 1 (2020): 33. http://dx.doi.org/10.26634/jcom.8.1.17166.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Yao, Linli, Jiaqi Han, Longjiang She, Dong Ding, Mengting Liao, Huabin Hu, Shan Zeng, Liangfang Shen, and Jin Huang. "Cost-effectiveness for metastatic colorectal cancer." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e15003-e15003. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e15003.

Full text

Abstract:

e15003 Background: As standard third-line treatments for metastatic colorectal cancer, regorafenib and fruquintinib, compared with placebo, increase median overall survival by 2.5 months and 2.7 months, respectively. Given the incremental clinical benefit, we aim to estimate the cost effectiveness of regorafenib versus fruquintinib in the third-line treatment for patients with metastatic colorectal cancer from Chinese payer perspective. Methods: A mathematical Markov model was established to project the cost-effectiveness of regorafenib versus fruquintinib from the CONCUR and FRESCO clinical trials. Quality-adjusted-life-years (QALYs) were analyzed with extracted data from the trials. Willingness to pay (WTP) of $26508 was used. Drug costs were estimated from the perspectives of the health care system in the People’s Republic of China. One way sensitivity and scenario analyses were performed by varying potentially modifiable parameters of the model. Results: Fruquintinib, compared with regorafenib, provided an additional 0.028 QALYs (0.274 QALYs versus 0.246 QALYs) at less cost ($33536 versus $35607). Conclusions: Fruquintinib is more cost-effective than regorafenib as the third-line management for patients with metastatic colorectal cancer when WTP is $26508.

APA, Harvard, Vancouver, ISO, and other styles

28

Hatswell, Anthony J., Ash Bullement, Andrew Briggs, Mike Paulden, and Matthew D. Stevenson. "Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models." PharmacoEconomics 36, no. 12 (July 27, 2018): 1421–26. http://dx.doi.org/10.1007/s40273-018-0697-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Lamrock, Felicity, Joanne O'Connor, Joy Leahy, Claire Gorry, Lesley Tilson, and Michael Barry. "OP97 Cost-effectiveness Model Appraisal Guidelines For Health Technology Assessments In Ireland." International Journal of Technology Assessment in Health Care 35, S1 (2019): 24–25. http://dx.doi.org/10.1017/s0266462319001478.

Full text

Abstract:

IntroductionThe National Centre for Pharmacoeconomics (NCPE) assesses the cost-effectiveness of new drugs for which reimbursement by the healthcare payer, the Health Service Executive (HSE), is sought in Ireland. This research aims to create a systematic approach for the NCPE review group (RG) to assess each of the cost-effectiveness models submitted by the applicant by creating cost-effectiveness model appraisal guidelines.MethodsThe RG consists of clinical, statistical and health economic expertise. In order to systematically appraise the HTA submission, which includes a cost-effectiveness model, clear guidelines on how each of the members of the RG can work together are required. The current members of the RG in the NCPE were given a draft of the guidelines created by the primary author, and additional feedback and testing was performed using the expert experience of the team. A version of the guidelines was tested for its usefulness.ResultsThree checklists were created. The purpose of the first checklist is to evaluate if the cost-effectiveness model works correctly. The second checklist ensures that each of the assumptions included in the HTA dossier are the same as those included in the cost-effectiveness model. The final checklist validates the assumptions used in the cost-effectiveness model to ensure they are reasonable and appropriate for decision making. The final version of the checklists were validated by choosing cost-effectiveness models with known errors and/or discrepancies and testing that the issues were captured by the checklists.ConclusionsThese guidelines are not an exhaustive list of checks that should be performed, but are presented as the minimum requirements for consideration to be included with each RG assessment of the corresponding HTA submission. The guidelines will be constantly updated as the process evolves over time. The cost-effectiveness models should follow the National Health Information and Quality Authority (HIQA) Guidelines for the Economic Evaluation of Health Technologies in Ireland.

APA, Harvard, Vancouver, ISO, and other styles

30

Negrín, Miguel A., and Francisco-José Vázquez-Polo. "Incorporating model uncertainty in cost-effectiveness analysis: A Bayesian model averaging approach." Journal of Health Economics 27, no. 5 (September 2008): 1250–59. http://dx.doi.org/10.1016/j.jhealeco.2008.03.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Park, Joon Yong, Yoon-Sook Kim, Jin Kook Kim, and Jae Hoon Cho. "Cost-Effectiveness Analysis of Immunotherapy in Patient with Allergic Rhinitis." Korean Journal of Otorhinolaryngology-Head and Neck Surgery 64, no. 8 (August 21, 2021): 554–62. http://dx.doi.org/10.3342/kjorl-hns.2020.00752.

Full text

Abstract:

Background and Objectives All treatments must be effective and affordable. Although it is clear that immunotherapy is effective in patients with allergic rhinitis, no cost-effectiveness analysis has been conducted in Korea.Subjects and Method We compared 10 years of total treatment costs (medical expense+ transportation cost+time cost) with medications and symptoms scores assuming that adult patients with allergic rhinitis are treated only with symptomatic medication (medication model) or immunotherapy (subcutaneous or sublingual) plus symptomatic medication [subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) models, respectively]. For cost-effectiveness analysis, related papers and domestic medical statistics were used.Results The total treatment costs for the first 3 years were ₩3330199, ₩6605557, and ₩7130467 for the Medication model, SCIT model and SLIT model, respectively. The total treatment costs for the 10-year period were ₩7996087, ₩8588624, and ₩9113534 for the medication model, SCIT model, and SCIT model, respectively. The cumulative symptoms plus medications scores decreased 0.44 times in both immunotherapy models compared to the medication model. Conclusion The initial cost of immunotherapy is more expensive than symptomatic medication, but the total cost for 10 years is similar. In addition, immunotherapy can reduce symptoms by more than half. Therefore, it is a cost-effective treatment for allergic rhinitis.

APA, Harvard, Vancouver, ISO, and other styles

32

Raab, Stephen S. "The Cost-Effectiveness of Immunohistochemistry." Archives of Pathology & Laboratory Medicine 124, no. 8 (August 1, 2000): 1185–91. http://dx.doi.org/10.5858/2000-124-1185-tceoi.

Full text

Abstract:

Abstract Objective.—To evaluate the cost-effectiveness of immunohistochemistry. Design.—Using a theoretical decision analytic model, the cost-effectiveness of immunohistochemistry was evaluated in different scenarios depicting the beneficial use of immunohistochemistry. Data regarding the effectiveness of immunohistochemistry were obtained from the medical literature and costs were obtained from Allegheny General Hospital. Settings.—The scenarios depicted both private practice and university patients from which anatomic pathology specimens were obtained. Immunohistochemistry was subsequently performed on these specimens. Main Outcome Measures.—Cost, life expectancy, diagnostic certainty, ability to predict prognosis, and cost-effectiveness were evaluated. Results.—In all scenarios, immunohistochemistry was cost-effective at very low efficacies. Assuming a per-antibody cost of $50 and use of a 5-antibody panel, immunohistochemistry was cost-effective if it resulted in a 1-year gain of population life expectancy in 1 or more of every 200 cases in which it was applied. Alternatively, if the gain in diagnostic certainty by using immunohistochemistry was 10% and the value placed on a percentage gain in diagnostic certainty was $1000, immunohistochemistry was cost-effective if it produced this increase in certainty in 1 of every 40 tests. If a life-year was valued at $50 000, immunohistochemistry was cost-effective if it resulted in a change in patient prognosis of 0.5 years in 1 of every 100 tests. Conclusions.—Using theoretical modeling, immunohistochemistry is extremely cost-effective. These data have implications in an era of managed care when providers attempt to trim laboratory services. Additional studies are needed to evaluate the actual practice efficacy of immunohistochemistry.

APA, Harvard, Vancouver, ISO, and other styles

33

Correia, M. I., M. Castro, and D. D. O. Toledo. "A nutrition therapy cost-effectiveness model informs potential cost-savings for healthcare, in Brazil." Clinical Nutrition ESPEN 40 (December 2020): 687. http://dx.doi.org/10.1016/j.clnesp.2020.09.850.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kietliński, Krzysztof M. "Retrofit of the Cost and Effectiveness Model in Large Enterprise." Economics and Organization of Enterprise 5, no. 3 (March 1, 2009): 84–90. http://dx.doi.org/10.2478/v10061-010-0026-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Mauskopf, Josephine A., Anke Richter, Lieven Annemans, and Grant Maclaine. "Cost-Effectiveness Model of Cytomegalovirus Management Strategies in Renal Transplantation." PharmacoEconomics 18, no. 3 (September 2000): 239–51. http://dx.doi.org/10.2165/00019053-200018030-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Berhe, Hailay Weldegiorgis, Oluwole Daniel Makinde, and David Mwangi Theuri. "Optimal Control and Cost-Effectiveness Analysis for Dysentery Epidemic Model." Applied Mathematics & Information Sciences 12, no. 6 (November 1, 2018): 1183–95. http://dx.doi.org/10.18576/amis/120613.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Abler, D., S. Harris, and J. Davies. "189 META-MODELLING MARKOV MODEL SIMULATIONS FOR COST EFFECTIVENESS ANALYSES." Radiotherapy and Oncology 102 (March 2012): S91. http://dx.doi.org/10.1016/s0167-8140(12)70160-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Yan, Charles, Susan Armijo-Olivo, Bing Guo, Yufei Zheng, Michael Hill, Balraj Mann, Thomas Jeerakathil, Noreen Kamal, Shy Amlani, and Andy W. Chuck. "OP49 An Alternative Cost-Effectiveness Model For Health Technology Delivery." International Journal of Technology Assessment in Health Care 34, S1 (2018): 19–20. http://dx.doi.org/10.1017/s0266462318001010.

Full text

Abstract:

Introduction:The cost-effectiveness of endovascular therapy (EVT) compared to tissue plasminogen activator (tPA) alone for acute ischemic stroke (AIS) has been established in the literature. However, decision-makers still face challenges of how to best deliver EVT in a timely manner to maximize patient outcomes while minimizing the burden to the healthcare system, given that AIS has time-dependent treatment outcomes. The objective of this presentation is to report an optimization approach for improving health system value and outcomes for patients with AIS who are eligible for EVT in Alberta.Methods:An economic model was developed to compare combinations of “mothership” (transport directly to a comprehensive stroke center [CSC] to receive tPA and EVT) and “drip-and-ship” (transport to a primary stroke centre to receive tPA, followed by transport to a CSC to receive EVT) methods across Alberta. The model considered geographical variation and searched for the best delivery methods through a pairwise comparison of all possible strategies. The controlled variables including in the model were population densities, disease epidemiology, time/distance to hospitals, available medical services, treatment eligibility and efficacy, and costs. Patient outcomes were measured by functional independence. The model defined optimal strategies by identifying the transport methods that produced the highest probability of improved health outcomes at the lowest cost.Results:The analysis produced an optimization map showing optimal strategies for EVT delivery. The lifetime cost (standard deviation [SD]) per patient and likelihood (SD) of good outcomes was CAD 291,769 (CAD 11,576) [USD 226,207 (USD 8,975)] and 41.82 percent (0.013) when considering optimal clinical outcomes, and CAD 287,725 (CAD 4,141) [USD 223,097 (USD 3,211)] and 41.67 percent (0.016) when considering optimal economic efficiency.Conclusions:Our model reduces the gap that exists between health technology implementation and cost-effectiveness analysis; namely, neither fully addresses relative efficiency driven by geographical variation, which may misrepresent system value in local settings. Implementation strategies generated in our model capture full values in terms of patient outcomes and costs.

APA, Harvard, Vancouver, ISO, and other styles

39

Soares, Marta O., Linda Sharples, Alec Morton, Karl Claxton, and Laura Bojke. "Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses." Value in Health 21, no. 6 (June 2018): 715–23. http://dx.doi.org/10.1016/j.jval.2018.01.019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Paulden, M. "PRM51 - A NEW CONCEPTUAL MODEL OF THE COST-EFFECTIVENESS THRESHOLD." Value in Health 21 (October 2018): S364. http://dx.doi.org/10.1016/j.jval.2018.09.2173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Sadler, S., I. Jacob, O. Darlington, E. Still, J. Gordon, M. Radford, and M. Gharaibeh. "PMS19 Validation of a Cost-Effectiveness MODEL in Rheumatoid Arthritis." Value in Health 23 (December 2020): S595. http://dx.doi.org/10.1016/j.jval.2020.08.1150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Visser, MS, S. Amarakoon, N. Dorrestijn, T. Missotten, and J. Busschbach. "PSS19 COST-EFFECTIVENESS OF AGE-RELATED MACULAR DEGENERATION: A MODEL." Value in Health 13, no. 7 (November 2010): A401. http://dx.doi.org/10.1016/s1098-3015(11)72648-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Petrou, Panagiotis. "Cost-effectiveness analysis of axitinib through a probabilistic decision model." Expert Opinion on Pharmacotherapy 16, no. 8 (May 9, 2015): 1233–43. http://dx.doi.org/10.1517/14656566.2015.1039982.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Vandewalle, Björn, Josep M. Llibre, Jean-Jacques Parienti, Andrew Ustianowski, Ricardo Camacho, Colette Smith, Alec Miners, Diana Ferreira, and Jorge Félix. "EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment." PLOS ONE 11, no. 2 (February 12, 2016): e0149007. http://dx.doi.org/10.1371/journal.pone.0149007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

König, Hans-Helmut, Anja Born, Dirk Heider, Herbert Matschinger, Sven Heinrich, Steffi G. Riedel-Heller, Daniel Surall, Matthias C. Angermeyer, and Christiane Roick. "Cost-effectiveness of a primary care model for anxiety disorders." British Journal of Psychiatry 195, no. 4 (October 2009): 308–17. http://dx.doi.org/10.1192/bjp.bp.108.058032.

Full text

Abstract:

BackgroundIndividuals with anxiety disorders often do not receive an accurate diagnosis or adequate treatment in primary care.AimsTo analyse the cost-effectiveness of an optimised care model for people with anxiety disorders in primary care.MethodIn a cluster randomised controlled trial, 46 primary care practices with 389 individuals positively screened with anxiety were randomised to intervention (23 practices, 201 participants) or usual care (23 practices, 188 participants). Physicians in the intervention group received training on diagnosis and treatment of anxiety disorders combined with the offer of a psychiatric consultation–liaison service for 6 months. Anxiety, depression, quality of life, service utilisation and costs were assessed at baseline, 6-month and 9-month follow-up.ResultsResultsNo significant differences were observed between intervention and control group on the Beck Anxiety Inventory, Beck Depression Inventory and EQ–5D during follow-up. Total costs were higher in the intervention group (€4911 v. €3453, P = 0.09). The probability of an incremental cost-effectiveness ratio <€50 000 per quality-adjusted life year was below 10%.ConclusionsThe optimised care model did not prove to be cost-effective.

APA, Harvard, Vancouver, ISO, and other styles

46

NEILSON, AILEEN R., and DAVID K. WHYNES. "Cost-effectiveness of screening for colorectal cancer: A simulation model." Mathematical Medicine and Biology 12, no. 3-4 (1995): 355–67. http://dx.doi.org/10.1093/imammb/12.3-4.355.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Slof, John, and Adrien Gras. "Sativex® in multiple sclerosis spasticity: a cost–effectiveness model." Expert Review of Pharmacoeconomics & Outcomes Research 12, no. 4 (August 2012): 439–41. http://dx.doi.org/10.1586/erp.12.40.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

&NA;. "Alteplase vs streptokinase assessed using a new cost-effectiveness model." Inpharma Weekly &NA;, no. 828 (March 1992): 8. http://dx.doi.org/10.2165/00128413-199208280-00013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Catterall, James S. "A Cost-Effectiveness Model for the Assessment of Educational Productivity." New Directions for Higher Education 1998, no. 103 (1998): 61–84. http://dx.doi.org/10.1002/he.10305.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Wild, D. M. "Surveillance for isocyanate asthma: a model based cost effectiveness analysis." Occupational and Environmental Medicine 62, no. 11 (November 1, 2005): 743–49. http://dx.doi.org/10.1136/oem.2004.016147.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!